Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Bellmunt, J ^a   Albiol, S ^a   de Olano, A Ramírez ^a   Pujadas, J ^a   Maroto, P ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bladder cancer; Chemotherapy; Gemcitabine; Urothelial cell cancer

Indexed keywords

ALPHA INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEFITINIB; GELATINASE B; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 8; METALLOPROTEINASE; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEIN P53; RETINOBLASTOMA PROTEIN; RIBONUCLEOTIDE REDUCTASE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VINBLASTINE; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; LUNG TOXICITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK BENEFIT ANALYSIS; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; COMORBIDITY; DEOXYCYTIDINE; DOXORUBICIN; HUMANS; KIDNEY FAILURE; METHOTREXATE; PHARMACOGENETICS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM; VINBLASTINE;

EID: 33745616821     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj964     Document Type: Article

References (61)

1. Loehrer P, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study. J Clin Oncol 1992; 10: 1066-73.
2. Logothetis CJ, Dexeus; F, Finn L et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastasic urothelial tumors. J Clin Oncol 1990; 8:1050-5.
3. Bellmunt J, Ribas A, Eres N et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80: 1966-72.
4. Hillcoat BL, Raghavan D, Matthews J et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 1989; 7: 706-9.
5. Stoter G, Splinter TA, Child JA et al. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 1987; 137: 663-7.
6. Harker W, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract a Northern California Oncology Group study. J Clin Oncol 1985; 3:1463-70.
7. Mead GM, Russell M, Clark P et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: Results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 1998; 78: 1067-75.
8. M. J. Moore, E. Winquist, E. E. Vokes et al. Phase II study of oxaliplatin in patients with inoperable, locally advanced or metastatic transitional cell carcinoma of the urothellal tract (TCC) who have received prior chemotherapy. Proc Am Soc Clin Oncol 2003; 22: 408 (abstr 1638).
9. Culine S, Rebillard X, Iborra F et al. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothellum: A pilot study. Anticancer Res 2003; 23: 1903-6.
10. Font A, Esteban E, Carles J et al. Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Proc Am Soc Clin Oncol 2004; 23: 391 (Abstract 4544).
11. Khorsand M, Lange J, Feun L et al. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest New Drugs 1997; 15: 157-163.
12. Sternberg CN. Gemcitabine in Bladder Cancer. Semin Oncol 2000;. 27: 31-9.
13. von der Meese H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003; 21: 11-9.
14. Misset JL. Brief communication: Use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer. Semin Oncol. 2002; 29 (1 Suppl 3): 36-9.
15. Sternberg, CN, Vogelzang, NJ. Gemcitabine, Paclitaxel, Pemetrexed and Other Newer Agents in Urothelial and Kidney Cancers. Crit Rev Oncol Hematol. 2003; 46 (Suppl: S10) 5-15.
16. Bellmunt J, Albioll S. New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol. 2001; 11: 517-22.
17. Calabró F, Sternberg CN. High-risk metastatic urothellal cancer: chances for cure? Curr Opin Urol 2002; 12(5): 441-8.
18. Calabró F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 2002; 20: 158-66.
19. Pollera CF, Ceribelli A, Grecco M et al. Weekly gemcitabine in advanced bladder cancer. A preliminary report from a phase I study. Ann Oncol 1994; 5: 182-184.
20. Lorusso V, Pollera CF, Antimi M et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34: 1208-1212.
21. Albers P, Siener R, Perabo F et al. Gemcitabine Monotherapy as 2nd-Line Treatment in Cisplatin Refractory Transitional Cell Carcinoma. Proc Am Soc Clin Oncol 2000; Abstr 1360.
22. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA: Phase II study of single-agent gemcitabine in previously untreated patents with metastatic urothelial cancer. J Clin Oncol 1997; 15: 3394-3398.
23. Moore MJ, Tannock I, Ernst S, Huan S, Murray N: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15: 3441-3445.
24. von der Maase H, Andersen L, Crino L et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial. Ann Oncol 1999; 10(12): 1641-1645.
25. Kaufman D, Raghavan D, Carducci M et al. Phase II trial of Gemcitabine plus Cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18(9): 1921-1927.
26. Moore MJ, Winquist E, Murray N. et al Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncoll 1999; 17, 2876-2880.
27. Stadler WM, Murphy B, Kaufman D et al. Phase II trial of gemcitabine (GEM) plus cisplatin (CDDP) in metastatic urothelial cancer (UC). Proc Am Soc Clin Oncol 1997; 16: A1152.
28. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18(17): 3068-77.
29. Bellmunt J, de Wit R, Albanell J et al. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 2001; 37: 2212-5.
30. Bajorin DF, McCaffrey JA, Dodd PM et al. Ifosfamide, Paclitaxel, and Cisplatin for Patients with Advanced Transitional Cell Carcinoma of the Urothelial Tract: Final Report of a Phase II Trial evaluating two Dosing Schedules. Cancer 2000; 88(7): 1671-8.
31. Dodd PM, McCaffrey JA, Hilton S et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifoslamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 2000; 18: 840-846.
32. Novick S, Higgins G, Hilton S et al. Phase VII sequential doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with transitional cell carcinoma and impaired renal function. Proc Am Soc Clin Oncol. 2000; 19: 361a (Abstr 1423).
33. Bellmunt J, Guillem V, Paz-Ares L et al. Phase I/II study of paclitaxel, cisplatin, and gemcitabine in advanced transitonal-cell carcinoma of the urothelium. J Clin Oncoll 2000; 18: 3247-3255.
34. Hussain M, Vaishampayan U, Du W et al. Combination carboplatin, paclitaxel and gemcitabine is an active treatment for advanced urothelial carcinoma. J Clin Oncol 2001; 19: 2527-2533,
35. Bamias A, Aravantinos G, Deliveliotis C. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus M-VAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22: 220-8.
36. Dreicer R, Manola J, Ruth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004; 100: 1639-45.
37. Siefker-Radtke AO, Millikan RE, Tu SM et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002; 20: 1361-7.
38. Vaughn D, Dreicer R, Manola J et al. E2896 paclitaxel/carboplatin in advanced urothelial carcinoma and renal insufficiency: A phase II trial of the Eastern Cooperative Group. Proc Am Soc Clin Oncol 2000; 19: 343 (Abstr 1351).
39. Turkolmez K, Beduk Y, Baltaci S et al. Gemcitabine plus vinorelbine Chemotherapy in Patients with Advanced Bladder Carcinoma Who Are Medically Unsuitable for or Who Have Failed Cisplatin-Based Chemotherapy. Eur Urol 2003; 44: 682-686.
40. Sternberg CN, Calabró F, Pizzocaro G et al. Chemotherapy with Every-2-Week Gemcitabine and Paclitaxel in Patients with Transitional Cell Carcinoma who have received prior Cisplatin-based therapy. Cancer 2001; 92: 2993-8.
41. Meluch AA, Greco FA, Burris HA et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A Phase II trial of the Minnie Pearl Cancer Research Network J Clin Oncol 2001; 19: 3018-24.
42. Parameswaran R, Fisch MJ, Ansari RH et al. A hossier oncology group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. Proc Am Soc Clin Oncol 2001; 200a, (Abstr 798).
43. Guardino AE, Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies. Proc Am Soc Clin Oncol 2002; 21: 150b (Abstr 321).
44. Fechner G. H., Siener R., Reimann M. et al. Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma. J Urol 2002; 167 (4 Suppl): 284.
45. Kaufmann DS, Carducci MA, Kuzel T et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): A completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC). Proc Am Soc Clin Oncol 2002; 21(1), 192a (Abstr 767)
46. Al-Sukhun S, Hussain M: Current understanding of the biology of advanced bladder cancer. Cancer 2003; 97(Suppl 8): 2064-75,
47. Petrylak DP, Scher HI, Reuter V et al. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 1994; 5: 835-840.
48. Pendyala L, Velagapudi S, Toth K et al. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res 1997; 13: 793-798.
49. Siu LL, Banerjee D, Khurana RJ et al. The prognostic role of p53, metallothionein, P-glycoprotein and MIB-1 in muscle invasive urothelial transitional cell carcinoma. Clin Cancer Res 1998; 4: 559-565.
50. Esring D, Elmaijian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-1264.
51. Cordon-Cardo C, Zhang Z-F, Dalbagni G et al. Cooperative effects of p53 and pRb alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217-21.
52. Zhang Z-T, Pak J, Huang H-Y et al. Role of H-Ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 2001; 20: 1973-80.
53. Sarkis A, Bajorin D, Reuter V et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1996; 13: 1384-90.
54. Edelman MJ, Meyers FJ, Miller TR et al. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: A well-tolerated regimen with activity independent of p53 mutation. Urology 2000; 55: 521-525.
55. Chow NH, Chan SH, Tzai TS et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7: 1957-1962.
56. Neal DE, Marsh C, Bennett MK et al. Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 1985; 1: 366-369.
57. Raghavan D: Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 2003; 97 (Suppl 8): 2083-89.
58. Bellmunt J, Trigo J, Garcia-Ribas I et al. Phase I Study of High-Dose Bi-Weekly Gemcitabine at a Constant Rate Infusion (CRI) without Growth Factor Support in Advanced Solid Tumors, Including Prior Standard Gemcitabine Treated Patients. Proc Am Soc Clin Oncol 2005; Abstr 2067.
59. Jimenez RE, Hussain M, Bianco FJ Jr et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7: 2440-2447.
60. Hussain M, Petrylak D, Dunn R et al. Trastuzumab (T), Paclitaxel (P), Carboplatin (C), and Gemcitabine (G) in Advanced HER2-positive Urothelial Carcinoma: Results of a Multi-Center Phase II NCI Trial 2005. Proc Am Soc Clin Oncol 2005; Abstr 4507.
61. Philips G, Halabi S, Sanford B et al. Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102. Proc Am Soc Clin Oncol 2004; Abstr 4540.